New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 28, 2014
14:25 EDTABT, ABT, ATRC, ATRC, BSX, BSX, EW, EW, MDT, MDT, STJ, STJ, VOLC, VOLCLeerink medical devices analyst holds an analyst/industry conference call
Medical Devices Analyst Antalffy, along with MEDACorp Specialist Arie Pieter Kappetein, MD, PhD and Bernhard Meier, MD, assess EU cardiology trends on an Analyst/Industry conference call to be held on July 31 at 3 pm.
News For ABT;ATRC;BSX;EW;MDT;STJ;VOLC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
July 21, 2015
13:56 EDTSTJSt. Jude Medical bid for Thoratec makes strategic sense, says JPMorgan
Subscribe for More Information
12:40 EDTSTJSt. Jude in talks to acquire Thoratec, Bloomberg reports
St. Jude Medical (STJ) is in talks to acquire Thoratec (THOR), Bloomberg reports, citing people familiar with the situation. Talks are ongoing and could still fall apart as no deal has been reached, Bloomberg adds. Thoratec shares spiked early in today's session, but a catalyst for the move was unclear before the Bloomberg report. Shares of the medical device maker focused on advanced heart failure patients are up $9.52 to $58.33 in midday trading. Its close competitor HeartWare (HTWR) is now up $5.53 to $84.70. Shares of St. Jude are up 4 to $76.61. Reference Link
12:33 EDTSTJThoratec jumps after Bloomberg report of St. Jude buyout talks
Subscribe for More Information
12:29 EDTSTJSt. Jude Medical in talks to acquire Thoratec, Bloomberg reports
Subscribe for More Information
12:21 EDTSTJOn The Fly: Top stock stories at midday
Subscribe for More Information
10:20 EDTSTJCatalyst behind Thoratec spike higher unclear
The catalyst behind the spike higher in shares of Thoratec (THOR) is unclear to traders and investors. The medical device maker focused on advanced heart failure patients rose as high $62.05 in early trading and its shares remain up 11%, or $5.48, to $54.29. Some vague takeover chatter surfaced, with St. Jude Medical (STJ) as the speculated buyer, but buyout rumors are often the "go-to" reason when stocks spike. Often the moves on rumors are less substantial than Thoratec's spike today. The company's close competitor HeartWare (HTWR) is not seeing any unusual trading thus far today, falling 36c to $78.81 in early trading.
07:22 EDTBSXBoston Scientific should be bought on pullbacks, says RBC Capital
RBC Capital expects Boston Scientific to report slightly higher than expected Q2 EPS and in-line revenue. The firm expects the company's results to be boosted by strength in ICDs and OUS DES stents. RBC is confident that the company's EPS can grow by low teen percentage levels over the long-term and recommends buying the shares on pullbacks.
July 20, 2015
09:08 EDTBSXBoston Scientific begins study of resorbable drug-eluting scaffold system
Boston Scientific has initiated a study of the company's first fully resorbable drug-eluting scaffold system. The Fully Absorbable Scaffold Feasibility Study, or FAST, is a prospective, single arm study designed to assess the safety and performance of this next generation scaffold for the treatment of atherosclerotic coronary lesions.
09:02 EDTABTAbbott receives FDA approval and launches iDesign Advanced WaveScan system
Subscribe for More Information
08:38 EDTABTAnalyst predicts Zoetis merges with Bayer unit, not Valeant
Zoetis (ZTS) in recent months has been the subject of takeover speculation, possibly for Valeant (VRX), but a Jefferies analyst told investors today in a research note that he views a deal with a unit of healthcare giant Bayer (BAYRY) as "highly likely" for the animal medicine company. BACKGROUND: Bill Ackman of Pershing Square, who owns stakes in both Zoetis and Valeant, said in early May while speaking on CNBC that Zoetis is a "great” business on a standalone basis, but he also spoke of the company's strategic value. Ackman added, however, that he was "not sure" that Valeant was the best acquirer of Zoetis. Subsequently, in late June, The Wall Street Journal reported that Valeant made a preliminary approach regarding a potential deal to buy Zoetis. CNBC's David Faber said the next day, citing his own sources, that Valeant reached out to Zoetis as a courtesy to common shareholder Ackman and was unlikely to pursue an acquisition of the company, though he cautioned then Valeant could change its approach and pursue a deal. BAYER: Jefferies analyst Jeffrey Holford said in a note today that he views a tie-up between Zoetis and Bayer's Animal Health business in 2016 as "highly likely." He sees Mylan's (MYL) acquisition of Abbott's (ABT) non‑U.S. developed markets specialty and branded generics business as a potential proxy for how a transaction could be structured, adding that such a "spinversion" could achieve up to 36% long-term earnings accretion for Zoetis. Holford reiterated a Buy rating on Zoetis with a $60 price target, while downgrading Bayer to Hold, citing valuation following the recent outperformance of its shares. IDEXX: While being discussed as a target, some analysts have also opined on companies that Zoetis could pursue as a buyer. On June 29, Canaccord said that in investor meetings with IDEXX (IDXX) executives declined to comment on Zoetis' potential interest in scaling up its animal health diagnostics business. Canaccord added that it thought Zoetis could make a bid for IDEXX. The firm reiterated its Buy rating and $80 price target on IDEXX shares at that time. PRICE ACTION: Since June 25, the day the Journal first reported on Valeant's preliminary takeover approach to Zoetis, the animal health company's shares have dropped nearly 4%. Zoetis closed down 20c to $47.80 on Friday.
08:32 EDTSTJSt. Jude Medical receives FDA approval for MR-conditional 5-column paddle lead
Subscribe for More Information
07:33 EDTABTInternational AIDS Society to hold a conference
Subscribe for More Information
07:30 EDTABTZoetis 'highly likely' to merge with Bayer unit in 2016, says Jefferies
Subscribe for More Information
July 17, 2015
08:07 EDTMDTMedtronic shares undervalued, says Wells Fargo
Subscribe for More Information
July 16, 2015
10:00 EDTMDTOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Arc Logistics (ARCX) upgraded to Buy from Hold at Stifel... Dean Foods (DF) upgraded to Buy from Hold at Deutsche Bank... FreightCar America (RAIL) upgraded to Neutral from Sell at UBS... Frontier Communications (FTR) upgraded to Buy from Hold at Jefferies... Google (GOOG) upgraded to Outperform from Market Perform at BMO Capital... Intel (INTC) upgraded to Buy from Hold at Needham... Medtronic (MDT) upgraded to Buy from Neutral at BTIG... Netflix (NFLX) upgraded to Buy from Neutral at Rosenblatt... New Jersey Resources (NJR) upgraded to Buy from Hold at Argus... ONEOK Partners (OKS) upgraded to Outperform from Perform at Oppenheimer... Patterson-UTI (PTEN) upgraded to Overweight from Equal Weight at Morgan Stanley... SJM Holdings (SJMHY) upgraded to Overweight from Underweight at JPMorgan... Statoil (STO) upgraded to Buy from Neutral at Citi... SunOpta (STKL) upgraded to Outperform from Sector Perform at Scotia Howard Weil... Viacom (VIAB) upgraded to Neutral from Sell at Citi... Walgreens Boots Alliance (WBA) upgraded to Outperform from Neutral at Credit Suisse... Werner (WERN) upgraded on 'compelling' valuation at Wells Fargo... Wisconsin Energy (WEC) upgraded to Outperform from Neutral at Baird... voxeljet (VJET) upgraded to Overweight from Neutral at Piper Jaffray.
08:34 EDTSTJSt. Jude Medical receives FDA approval for spinal cord stimulation trial system
St. Jude Medical (STJ) announced it received FDA approval of the Invisible Trial System. The system, which received CE Mark in June 2015, is fully wireless and leverages Apple (AAPL) technology for both the patient and physician controllers. The system is designed to provide patients a more improved and discreet spinal cord stimulation, or SCS, trial experience. "Patients undergoing SCS trials consistently tell us about challenges they find in navigating the SCS trial system, from programming the device, to discomfort from the programming cables, to management of both issues. These hindrances may impede the integration of the technology into their daily activities, which shifts their focus away from evaluating the effectiveness of SCS therapy,” said pain specialist Dr. Jason E. Pope, president of Summit Pain Alliance in Santa Rosa, California. “By providing a discreet trial system, St. Jude Medical will help patients focus more on their potential pain relief and functional improvements, and less about the burdens common to traditional trial systems.”
07:42 EDTMDTMedtronic upgraded to Buy from Neutral at BTIG
BTIG upgraded Medtronic to Buy with a $89 price target. The firm believes the recent pullback has provided a buying opportunity and views the company as well positioned for growth with revenue upside, strong cash deployment, and more Covidien synergies than some expect.
05:54 EDTMDTMedtronic recalls Shiley neonatal, pediatric tracheostomy tubes
Subscribe for More Information
July 15, 2015
11:08 EDTABTFormula makers slip after Mead Johnson cuts guidance
Subscribe for More Information
07:29 EDTMDTAmerican Orthopaedic Foot & Ankle Society to hold annual meeting
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use